STRIDES PHARMA SCIENCE
|
STRIDES PHARMA SCIENCE Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -22.44 | -51.25 | 29.93 | 4.06 | 36.25 |
| CEPS(Rs) | 1.37 | -26.87 | 50.19 | 24.23 | 23.08 |
| DPS(Rs) | 1.50 | - | 2.50 | 14.00 | 3.00 |
| Book NAV/Share(Rs) | 242.83 | 262.48 | 309.09 | 281.55 | 294.94 |
| Tax Rate(%) | 19.32 | 27.32 | 11.49 | 20.71 | -43.04 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 6.17 | -0.40 | 11.45 | 10.95 | 7.26 |
| EBIT Margin(%) | -0.40 | -8.93 | 7.77 | 4.47 | 4.25 |
| Pre Tax Margin(%) | -4.58 | -12.25 | 5.03 | 1.16 | 1.87 |
| PAT Margin (%) | -3.70 | -8.90 | 4.45 | 0.92 | 2.67 |
| Cash Profit Margin (%) | 0.20 | -4.53 | 8.22 | 4.61 | 6.19 |
| Performance Ratios | |||||
| ROA(%) | -3.52 | -6.99 | 3.82 | 0.63 | 1.24 |
| ROE(%) | -10.15 | -18.49 | 9.21 | 1.68 | 3.50 |
| ROCE(%) | -0.49 | -9.49 | 9.08 | 4.06 | 2.61 |
| Asset Turnover(x) | 0.95 | 0.78 | 0.86 | 0.68 | 0.46 |
| Sales/Fixed Asset(x) | 1.91 | 1.75 | 2.04 | 1.43 | 0.92 |
| Working Capital/Sales(x) | 43.06 | -106.88 | 69.38 | -27.04 | 8.63 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.52 | 0.57 | 0.49 | 0.70 | 1.09 |
| Receivable days | 73.25 | 79.41 | 68.09 | 74.33 | 102.23 |
| Inventory Days | 67.80 | 81.35 | 66.13 | 64.17 | 78.00 |
| Payable days | 230.40 | 267.95 | 264.54 | 274.24 | 269.25 |
| Valuation Parameters | |||||
| PER(x) | - | - | 28.21 | 79.39 | 13.01 |
| PCE(x) | 209.18 | -12.90 | 16.83 | 13.31 | 20.44 |
| Price/Book(x) | 1.18 | 1.32 | 2.73 | 1.15 | 1.60 |
| Yield(%) | 0.52 | - | 0.30 | 4.34 | 0.64 |
| EV/Net Sales(x) | 1.37 | 1.86 | 2.86 | 1.68 | 3.18 |
| EV/Core EBITDA(x) | 9.69 | 51.09 | 13.84 | 8.11 | 24.46 |
| EV/EBIT(x) | -201.23 | -12.01 | 22.32 | 21.93 | 48.88 |
| EV/CE(x) | 0.79 | 0.85 | 1.39 | 0.77 | 0.89 |
| M Cap / Sales | 0.70 | 1.01 | 2.28 | 1.05 | 1.94 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 20.13 | -7.41 | 20.49 | 26.33 | -23.43 |
| Core EBITDA Growth(%) | 365.23 | -83.70 | 20.61 | 100.96 | -42.28 |
| EBIT Growth(%) | 94.73 | -211.81 | 102.24 | 48.50 | -48.70 |
| PAT Growth(%) | 51.31 | -294.53 | 462.28 | -51.42 | 20.19 |
| EPS Growth(%) | 56.22 | -271.23 | 636.70 | -88.79 | -51.18 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 1.27 | 1.18 | 0.76 | 0.78 | 1.22 |
| Current Ratio(x) | 1.05 | 0.99 | 1.03 | 0.93 | 1.15 |
| Quick Ratio(x) | 0.67 | 0.64 | 0.59 | 0.62 | 0.82 |
| Interest Cover(x) | -0.10 | -2.69 | 2.84 | 1.35 | 1.79 |
| Total Debt/Mcap(x) | 1.07 | 0.90 | 0.28 | 0.68 | 0.76 |
Compare Financial Ratios of peers of STRIDES PHARMA SCIENCE
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| STRIDES PHARMA SCIENCE | ₹8,107.0 Cr | 0.5% | -4.2% | 183.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹356,625.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹112,938.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹101,315.0 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,276.9 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹93,921.9 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
STRIDES PHARMA SCIENCE Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| STRIDES PHARMA SCIENCE | 0.5% |
-4.2% |
183.8% |
| SENSEX | 1.3% |
2.6% |
24% |
You may also like the below Video Courses
